Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47) by 29.68 percent. This is a 17.57 percent increase over losses of $(2.96) per share from the
Passage Bio lost less money than people expected—that's good news when a company is still spending a lot on research. Watch if the company keeps improving its spending while working on its treatments.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.